A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Exclusion Criteria

• •Women of childbearing potential or who are currently pregnant or lactating.
• •Presence of \> 20 draining fistulas at screening and baseline.
• •Participants with concurrent conditions or history of other diseases as follows:
• •* Any clinically significant medical condition other than HS, as determined by the investigator, that is not adequately controlled with appropriate treatment.
• •* Any other active skin disease or condition (eg, bacterial, fungal, or viral infection) that may interfere with the course, severity, or assessments of HS.
• •* Active systemic viral infection or any active viral infection that, based on the investigator's clinical assessment, make the participant an unsuitable candidate for the study.
• •* Current herpes zoster infection, a history of recurrent herpes zoster, a history of disseminated herpes simplex, or a history of herpes zoster.
• •* History of malignancy, including lymphoma and leukemia within 5 years before baseline, other than a successfully treated nonmetastatic cutaneous squamous cell carcinoma, basal cell carcinoma, or localized carcinoma in situ of the cervix.
• •* Albinism.
• •Prolonged QT interval corrected for heart rate using Fridericia's formula (QTcF), defined as ≥ 450 msec.
• •Positive test result for tuberculosis (TB) from the QuantiFERON-TB Gold test, or equivalent, at screening (or, if 2 indeterminate tests or not available, then as evaluated by a purified protein derivative test with a result of \< 5 mm of induration within 3 months of screening) or a history of active TB.
• •Positive serology test results for HIV, HBsAg, hepatitis B virus (HBV) core antibody, or HCV (HCV antibody with positive HCV-RNA) at screening.
• •Decreased blood cell counts at screening as per protocol-defined parameters.
• •Severely impaired liver function (Child-Pugh Class C) or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels ≥ 1.5 × upper limit of normal (ULN).
• •Impaired renal function with serum creatinine \> 1.5 mg/dL.
• •Use of prohibited medications per protocol-defined criteria.
• •Known or suspected allergy to INCB054707 or any component of the study drug.
• •Known history of clinically significant drug or alcohol abuse in the last year prior to baseline.
• •Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.